

Variant: NM_001079804.3:c.1564C>T

Version: 1.0

CA294895008 [↗](#)

972746 (ClinVar) [↗](#)

Gene: GAA ([HGNC:2548](#))

Condition: glycogen storage disease II ([MONDO:0009290](#))

Inheritance Mode: Autosomal recessive inheritance

UUID: 8d0b8d64-db57-46e0-9793-2c38dcff3359

Approved on: 2024/3/19

Published on: 2024/3/26

HGVS expressions

NM_001079804.3:c.1564C>T

NC_000017.11:g.80110953C>T

CM000679.2:g.80110953C>T

NC_000017.10:g.78084752C>T

CM000679.1:g.78084752C>T

NC_000017.9:g.75699347C>T

NG_009822.1:g.14398C>T

ENST00000570803.6:c.1564C>T

ENST00000572080.2:c.1564C>T

ENST00000577106.6:c.1564C>T

ENST00000302262.8:c.1564C>T

ENST00000302262.7:c.1564C>T

ENST00000390015.7:c.1564C>T

NM_000152.3:c.1564C>T

NM_001079803.1:c.1564C>T

NM_001079804.1:c.1564C>T

NM_000152.4:c.1564C>T

NM_001079803.2:c.1564C>T

NM_001079804.2:c.1564C>T

NM_000152.5:c.1564C>T

NM_001079803.3:c.1564C>T

Likely Pathogenic

Met criteria codes 4

PS3_Moderate

PP4_Moderate

PP3

PM2_Supporting

Not Met criteria codes 1

PM3

Evidence Links 0

Expert Panel

Lysosomal Diseases VCEP [↗](#)

Criteria Specification Information

[↗](#) **Criteria Specification:** ClinGen Lysosomal Storage Disorders Variant Curation Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2

[↗](#) PDF

[↗](#) **Criteria Specification Approval History**

[↗](#) **Criteria Specifications for this VCEP**

Lysosomal Diseases VCEP

The NM_000152.5:c.1564C>T variant in GAA is a missense variant predicted to cause substitution of proline by serine at amino acid 522 (p.Pro522Ser). Two probands with a confirmed diagnosis of IOPD have been reported with this variant (PMID: 32518148, 38250073), both CRIM-positive, one with documented symptoms of IOPD and the other on ERT (PP4_Moderate). Both probands are compound heterozygotes for the variant and other variants that have yet to be classified by the ClinGen Lysosomal Diseases VCEP (PM3_Not Met). This variant has a minor allele frequency in gnomAD v2.1.1 of 0.00001761 in the European (non-Finnish) population, which is lower than the ClinGen Lysosomal Diseases VCEP threshold (<0.001) for PM2, meeting this criterion. Functional assays support a deleterious effect of this variant, when expressed in COS cells, this variant was classified as Class B ("potentially less severe"). This includes 0.8% GAA activity in cells and 0.8% in medium, and evidence of abnormal synthesis and processing on Western blot (PMID: 22644586) (PS3_Moderate). The computational predictor REVEL gives a score of 0.932 which is higher than the ClinGen LD VCEP threshold for PP3 (>0.7) and therefore meets this criterion. There is a ClinVar entry for this variant (Variation ID: 972746). In summary, this variant meets the criteria to be classified as Likely Pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen Lysosomal Diseases VCEP: PP4_Moderate, PS3_Moderate, PM2_Supporting, PP3. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on March 19, 2024).

Met criteria codes

PS3_Moderate			When expressed in COS cells, this variant results in 0.8% GAA activity in cells, and there is evidence of abnormal synthesis and processing on Western blot (PMID: 22644586). This meets the ClinGen Lysosomal Diseases VCEP's specifications for PS3_Moderate.
PP4_Moderate			The variant has been detected in three patients with Pompe disease, including one patient who was CRIM-positive and a confirmed diagnosis of IOPD based on low GAA enzyme activity (PMID: 38250073). Another individual was also CRIM-positive and diagnosed with IOPD, however, individual results of GAA activity were not reported (PMID: 32518148). This variant was also seen in a patient with Pompe disease but the GAA activity was not given (PMID: 18425781) (PP4_Moderate).
PP3			The computational predictor REVEL gives a score of 0.932 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3).
PM2_Supporting			The highest population minor allele frequency in gnomAD v2.1.1 is 0.00001761 (2/113602 alleles) in the European (non-Finnish) population, which is lower than the ClinGen Lysosomal Diseases VCEP's threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). The highest population minor allele frequency in gnomAD v4.0.0 is 0.000008475 (10/1179962 alleles in the European (non-Finnish) population, which is lower than the ClinGen Lysosomal Diseases VCEP's threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting).

Not Met criteria codes

PM3			This variant has been detected in 2 individuals with Pompe disease. Both individuals were compound heterozygotes for the variant and a variant that has not been classified by the ClinGen LD VCEP. The phase is not confirmed for any of these individuals. One individual was homozygous for this variant (0 points; PM3_Not Met).
------------	---	---	--











Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.